There's also a great deal more focus on compliance, which certainly positions us well with our high-quality products.The Asia Pacific region also had a solid quarter, particularly in the Japanese market, due to strong sales in sleep, as well as our bilevel and respiratory product portfolio, which also did very well.
ResMed Management Discusses Q4 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts